ERX-208
ERX-208 is an anticancer agent that induces endoplasmic reticulum stress by targeting lysosomal acid lipase A (LIPA), ultimately leading to cancer cell apoptosis. ERX-208 can be used in ovarian cancer research.
For research use only. We do not sell to patients.
- CAS No.: 2440087-57-8
- Formula: C47H52N6O10
- Molecular Weight:860.95
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
ERX-208 (6 days) potently reduces cell viability across all five subtypes of ovarian cancer cells with an IC50 of ~100 nM and shows minimal cytotoxicity toward normal ovarian surface epithelial cells[1].
ERX-208 significantly impairs the long-term proliferative potential of ovarian cancer cells as measured by colony formation assays[1].
ERX-208 (500 nM) induces caspase-dependent apoptosis in ovarian cancer cells, with no evidence of ferroptosis or necroptosis induction[1].
ERX-208 (1 μM; 0-48 h) robustly activates the endoplasmic reticulum stress response in diverse ovarian cancer models at the transcriptional, post-transcriptional, and ultrastructural levels[1].
ERX-208 (1 μM; 0-16 h) -mediated endoplasmic reticulum stress response and cytotoxicity in SKOV3 ovarian cancer cells are dependent on LIPA expression[1].
ERX-208 (22 h) potently suppresses the invasive capacity of ascites-derived ovarian cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Parental SKOV3, SKOV3 LIPA-knockout (LIPA-KO)
-
Concentration:1 μM (RT-PCR/RT-qPCR); range of concentrations (cell viability assay)
-
Incubation Time:0, 8, 16 h (RT-PCR/RT-qPCR); unspecified (cell viability assay)
-
Result:Reduced cell viability and robustly induced XBP1 splicing, sXBP1 mRNA, and CHOP mRNA expression in parental SKOV3 cells following treatment.
Displayed markedly reduced sensitivity in SKOV3 LIPA-KO cells, with no significant induction of XBP1 splicing, sXBP1 mRNA, or CHOP mRNA expression.
In Vivo
ERX-208 (2.5-10 mg/kg; i.p.; once every three days; for a total of 11 days) dose-dependently inhibits the growth of OCa30 PDX tumors in SCID mice; among all groups, the 10 mg/kg group shows the greatest reduction in tumor weight, the most significant downregulation of Ki67 expression, and the most prominent upregulation of GRP78 expression, with no obvious systemic toxicity observed[1].
ERX-208 (10 mg/kg; i.p.; once every three days; for 21 consecutive days) significantly inhibits the growth of OCa14 PDX tumors in SCID mice and reduces the final tumor weight, while downregulating the expression of Ki67 and upregulating the expression of GRP78 in tumor tissues, with no obvious systemic toxicity[1].
ERX-208 (10 mg/kg; i.p.; once every three days; for a total of 39 days) significantly inhibits the growth of OCa10 PDX tumors in SCID mice and reduces the final tumor weight, while downregulating Ki67 expression, upregulating GRP78 expression and activating the endoplasmic reticulum stress pathway, with no obvious systemic toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID mice (8-week-old female; orthotopic xenograft model via intraperitoneal injection of ES2 GFP-Luciferase-expressing ovarian cancer cells)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; 5 days per week for 15 consecutive days
-
Result:Reduced ovarian cancer tumor burden by approximately 60% compared to vehicle controls.
Significantly decreased final tumor weight compared to vehicle controls.
Significantly reduced the number of peritoneal metastatic tumor nodules compared to vehicle controls.
Caused no significant changes in mouse body weight, indicating good tolerability.
-
Animal Model:SCID mice (8-week-old female; ectopic OCa30 patient-derived xenograft model)[1]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:i.p.; once every three days; for a total of 11 days
-
Result:Inhibited tumor growth in a dose-dependent manner, with the most significant suppression at the 10 mg/kg dose.
Significantly lowered final tumor weights in all treated groups, with the greatest reduction at 10 mg/kg.
Decreased the proliferation marker Ki67 in a dose-dependent manner in tumor tissue.
Increased the endoplasmic reticulum stress marker GRP78 in a dose-dependent manner in tumor tissue.
Caused no significant changes in mouse body weight across all dosing groups.
-
Animal Model:SCID mice (8-week-old female; ectopic OCa14 patient-derived xenograft model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; once every three days; for 21 consecutive days
-
Result:Significantly inhibited tumor growth throughout the study period compared to vehicle controls.
Markedly decreased final tumor weight compared to vehicle controls.
Significantly decreased Ki67-positive proliferative cells in tumor tissue.
Significantly increased GRP78 expression in tumor tissue.
Caused no significant changes in mouse body weight.
-
Animal Model:SCID mice (8-week-old female; ectopic OCa10 patient-derived xenograft model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; once every three days; for a total of 39 days
-
Result:Significantly inhibited tumor growth kinetics compared to vehicle controls.
Significantly decreased final tumor weight compared to vehicle controls.
Significantly decreased Ki67-positive proliferative cells in tumor tissue.
Significantly increased GRP78 expression in tumor tissue.
Activated additional endoplasmic reticulum stress markers including p-eIF2α, p-PERK, and CHOP in tumor tissue.
Caused no significant changes in mouse body weight.
Chemical Information
-
CAS No. 2440087-57-8
-
Molecular Weight 860.95
-
Formula C47H52N6O10
-
SMILES
OCCOC1=C([N+]([O-])=O)C=CC(C(NC(C(OCC(C)C)=C2)=CC=C2C(NC3=C(OCC(C)C)C=C(C(N[C@@H]4CC[C@@H](C(NC5=CN=C(C=CC=C6)C6=C5)=O)CC4)=O)C=C3)=O)=O)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- ERX-208
- 2440087-57-8
- ERX208
- ERX 208
- Lipase
- Apoptosis
- SKOV3 ovarian cancer cells
- SCID mouse xenografts
- unfolded protein response
- ovarian cancer explant models
- Lysosomal acid lipase A (LIPA)
- normal ovarian surface epithelial cells
- PDX tumor
- endoplasmic reticulum stress
- ovarian cancer cells
- caspase-dependent apoptosis
- Inhibitor
- inhibitor
- inhibit